

Special Issue

Advanced Research in the Pathophysiology and Treatment of Diabetes Mellitus

Message from the Guest Editor

Diabetes mellitus, the contemporary metabolic pandemic, represents a complex multifactorial syndrome characterized by abnormalities in every single aspect of cellular energy metabolism. Type 1 diabetes mellitus (T1DM) is associated with reduced endogenous insulin secretion as a result of progressive autoimmune destruction of insulin-producing pancreatic β -cells. Type 2 diabetes mellitus (T2DM) is associated with both insulin resistance and defective insulin secretion. Beyond T1DM and T2DM, distinct phenotypes of diabetes with varying degrees of insulin resistance and pancreatic β -cell defects have been characterized in the literature.

The aim of this special issue is to provide a platform for sharing all the novel insights into the pathophysiology and treatment of diabetes mellitus. Both original research and comprehensive review articles on this topic are invited for submission. The aim of this special issue is to provide a platform for sharing all the novel insights into the pathophysiology and treatment of diabetes mellitus. Both original research and comprehensive review articles on this topic are invited for submission.

Guest Editor

Dr. Chrysi Koliaki

First Propaedeutic Department of Internal Medicine and Diabetes Center, National Kapodistrian University of Athens, Laiko University Hospital, 11527 Athens, Greece

Deadline for manuscript submissions

closed (30 April 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/157284

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).